Uliledlimab

尤莱利单抗

Report date: 2026/03/27 20:01:50

Base Information

Drug NameUliledlimab
Drug Alias NameTJ-4309TJ-004309TJD-5
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of Action5'-nucleotidase inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
Targets5'-nucleotidase
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesI-Mab Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesI-Mab Biopharma Us LtdSanofiPt Kalbe Genexine Biologics +[4] 
Inactive CompaniesTracon Pharmaceuticals Inc
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[7] 
Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG